ArticleCytotechnology2025
Glabridin alleviates ischemic stroke-induced neurodamage via the PI3K/Akt pathway.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide; however, effective neuroprotective therapies remain limited. Glabridin, a flavonoid from licorice, exhibits antioxidant and anti-inflammatory properties, making it a candidate for stroke therapy. To evaluate the therapeutic potential and mechanisms of glabridin in IS, we combined computational and experimental approaches. Network pharmacology and molecular docking were used to predict potential targets and pathways of glabridin in ischemic stroke. Functional validation employed a transient middle cerebral artery occlusion/reperfusion (tMCAO/R) mouse model (behavioral testing, TTC, HE, TUNEL/Nissl staining, and biochemical assays) and an in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model in HT22 neuronal cells (cell viability assays and Western blot analysis). We found that glabridin significantly reduced infarct volume and improved neurological and motor function in MCAO/R mice, decreased neuronal apoptosis, attenuated inflammatory and oxidative stress markers (TNF-α, MDA) and increased antioxidant activity (SOD). In HT22 cells glabridin reduced OGD/R-induced apoptosis and restored cell viability. Mechanistically, both molecular docking and biochemical assays indicated that glabridin activates the PI3K/Akt signaling pathway, which likely mediates its neuroprotective effects. In summary, our integrative study demonstrates that glabridin ameliorates ischemia/reperfusion injury through anti-apoptotic, anti-inflammatory and antioxidant actions associated with PI3K/Akt activation, supporting further preclinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.